Drug intelligence / Profile preview

depigmented glutaraldehyde-polymerized birch pollen allergenic extract

Development stage
Unknown
Lead developer
Leti Pharma
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Depigmented glutaraldehyde-polymerized birch pollen allergenic extract, marketed under the brand name **Depigoid Birch**, is a modified allergen extract (allergoid) used for subcutaneous allergen immunotherapy (SCIT). The manufacturing process involves depigmentation with mild acid to remove low molecular weight compounds and polymerization with glutaraldehyde to cross-link proteins. This modification significantly reduces the extract's allergenicity (IgE binding) while preserving its immunogenicity (T-cell epitopes), allowing for the safe administration of higher allergen doses. It is primarily indicated for the treatment of birch pollen-induced allergic rhinitis, allergic rhinoconjunctivitis, and intermittent asthma. Clinical studies have also explored its efficacy in birch pollen-sensitized patients with atopic dermatitis. The extract is typically adsorbed on aluminum hydroxide and aims to induce immune tolerance, characterized by a shift from a Th2 to a Th1/Treg immune response and the production of allergen-specific IgG4 antibodies.

Brand names
Depigoid BirchDepigoid Abedul
Other names
depigmented polymerized birch pollen extractDPP birch pollen extractbirch pollen allergoid
02

Targets

Bet v 1

Beyond the preview

Go deeper on depigmented glutaraldehyde-polymerized birch pollen allergenic extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on depigmented glutaraldehyde-polymerized birch pollen allergenic extract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call